Albiglutide
Sources
registry, as of 2017-08-17Stale
https://clinicaltrials.gov/study/NCT00537719
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.. Overall status COMPLETED. Phases PHASE1. Lead sponsor GlaxoSmithKline. Enrollment 34. Conditions Diabetes Mellitus, Type 2. This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
ClinicalTrials.gov NCT00537719 protocol and results modules
registry, as of 2019-07-12Stale
https://clinicaltrials.gov/study/NCT02750930
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects. Overall status TERMINATED. Phases PHASE4. Lead sponsor GlaxoSmithKline. Enrollment 8. Conditions Diabetes Mellitus, Type 2. Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US) Food and Drug Administration (FDA), the European Medic
ClinicalTrials.gov NCT02750930 protocol and results modules
registry, as of 2017-01-09Stale
https://clinicaltrials.gov/study/NCT00849017
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor GlaxoSmithKline. Enrollment 309. Conditions Diabetes Mellitus, Type 2. The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
ClinicalTrials.gov NCT00849017 protocol and results modules
registry, as of 2018-04-05Stale
https://clinicaltrials.gov/study/NCT02496221
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects. Overall status COMPLETED. Phases PHASE4. Lead sponsor GlaxoSmithKline. Enrollment 20. Conditions Diabetes Mellitus, Type 2. Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus. The primary objective of this study is to assess if a single dose of albiglutide can affect cholecystokinin-induced gallbladder emptyin
ClinicalTrials.gov NCT02496221 protocol and results modules
registry, as of 2017-02-28Stale
https://clinicaltrials.gov/study/NCT01098539
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.. Overall status COMPLETED. Phases PHASE3. Lead sponsor GlaxoSmithKline. Enrollment 507. Conditions Diabetes Mellitus, Type 2. This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately cont
ClinicalTrials.gov NCT01098539 protocol and results modules
registry, as of 2026-08-13Stale
https://clinicaltrials.gov/study/NCT05220917
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study. Overall status ACTIVE_NOT_RECRUITING. Phases not stated. Lead sponsor Brigham and Women's Hospital. Enrollment 781430. Conditions Cardiovascular Events; Type2 Diabetes; Renal Disease. To perform an observational analysis to emulate a target trial (i.e., a hypothetical pragmatic trial that would have answered the causal question of interest) comparing the effectiveness and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 rec
ClinicalTrials.gov NCT05220917 protocol and results modules